Structural optimization of diphenylpyrimidine derivatives (DPPYs) as potent Bruton's tyrosine kinase (BTK) inhibitors with improved activity toward B leukemia cell lines-Reference-Cited by-同舟云学术

Structural optimization of diphenylpyrimidine derivatives (DPPYs) as potent Bruton's tyrosine kinase (BTK) inhibitors with improved activity toward B leukemia cell lines

Published:2017-01 Issue: Volume:126 Page:444-455
ISSN:0223-5234
Container-title:European Journal of Medicinal Chemistry
language:en
Short-container-title:European Journal of Medicinal Chemistry

Author:

Zhao Dan,Huang Shanshan,Qu Menghua,Wang Changyuan,Liu Zhihao,Li Zhen,Peng Jinyong,Liu Kexin,Li Yanxia,Ma Xiaodong,Shu Xiaohong

Funder

National Natural Science Foundation of China

Health and Family Planning Commission of Liaoning Province

Natural Science Foundation of Liaoning Province

Cultivation Project of Youth Techstars

Publisher

Elsevier BV

Subject

Organic Chemistry,Drug Discovery,Pharmacology,General Medicine

Reference33 articles.

1. Tec kinases: modulators of lymphocyte signaling and development;Lewis;Curr. Opin. Immunol.,2001

2. Development of a scalable synthesis of a Bruton's tyrosine kinase inhibitor via C−N and C−C bond couplings as an end game Strategy;Hong;Org. Process Res. Dev.,2014

3. Discovery of novel Bruton's tyrosine kinase (BTK) inhibitors bearing a pyrrolo [2,3-d] pyrimidine scaffold;Zhao;Bioor. Med. Chem.,2015

4. New insights into pre-BCR and BCR signaling with relevance to B cell malignancies;Rickert;Nat. Rev. Immunol.,2013

5. Chronic active B-cell-receptor signaling in diffuse large B-cell lymphoma;Davis;Nature,2010

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pyrimidine compounds BY4003 and BY4008 inhibit glioblastoma cells growth via modulating JAK3/STAT3 signaling pathway;Neurotherapeutics;2024-08

2. Recent research of BTK inhibitors: Methods of structural design, pharmacological activities, manmade derivatives and structure–activity relationship;Bioorganic Chemistry;2023-09

3. Quantification of orelabrutinib in human plasma and cerebrospinal fluid by liquid chromatography tandem mass spectrometry;Journal of Chromatography B;2023-04

4. Review of the development of BTK inhibitors in overcoming the clinical limitations of ibrutinib;European Journal of Medicinal Chemistry;2022-02

5. Research Progress of BTK Inhibitors in the Treatment of Inflammatory and Autoimmune Diseases;Hans Journal of Medicinal Chemistry;2022